Scott Gottlieb can start work now reshaping the FDA to meet lawmakers’ expectations for an agency that can speed up new drug approvals even more, without sacrificing the gold standard on safety and efficacy data that protect patients’ health.
Health and Human Services Secretary Tom Price swore Gottlieb in on Thursday morning, making him the nation’s 23rd Commissioner of Food and Drugs.
A physician, cancer survivor, FDA veteran and biopharma investor and consultant, Gottlieb was hammered by Democrats for his close business ties in the industry, which Republicans celebrated as a sign of experience and expertise. A clear favorite in biopharma circles among all the names in circulation for the job, Gottlieb will have broad power to set speed and safety limits for the agency and drug developers.
Everyone in this business will be watching every step.
Get Endpoints News in your inbox
News reports for those who discover, develop, and market drugs. Join 16,000+ biopharma pros who read Endpoints News articles by email every day. Free subscription.
You're subscribing to Endpoints News
John Carroll, Editor and Co-Founder
We produce two daily newsletters designed to give you a complete picture of what's important in biopharma.